Immunotherapy for non-small-cell lung cancer: The past 10 years

Future Oncology

Volumn 11, Issue 19, 2015, Pages 2681-2695

  Vansteenkiste, Johan ^a   Craps, Julie ^a   De Brucker, Nele ^a   Wauters, Isabelle ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

cancer vaccination; checkpoint inhibitors; immunotherapy; non small cell lung cancer; receptors, CTLA 4; receptors, PD L1; review

Indexed keywords

ANTINEOPLASTIC AGENT; AVELUMAB; BELAGENPUMATUCEL L; BMS 936559; DURVALUMAB; IPILIMUMAB; MELANOMA ANTIGEN 3 VACCINE; MONOCLONAL ANTIBODY; MPDL 3280A; NIMOTUZUMAB; NIVOLUMAB; PEMBROLIZUMAB; RACOTUMOMAB; TECEMOTIDE; TG 4010; TICILIMUMAB; UNCLASSIFIED DRUG;

ARTHRITIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER STAGING; CARDIOMYOPATHY; DIARRHEA; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; FOLLOW UP; HEPATITIS; HUMAN; HYPOPHYSITIS; IMMUNE RESPONSE; IMMUNOMODULATION; MYOCARDITIS; NEPHRITIS; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RASH; REVIEW; THYROIDITIS;

EID: 84943750570     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.116     Document Type: Review

References (56)

1. Vansteenkiste J, De Ruysscher D, Eberhardt W., et al. Early and locally advanced non-small cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24(Suppl 6), vi89-vi98 (2013
2. Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S. Metastatic non-smallcell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25(Suppl 3), iii27-iii39 (2014
3. Mok TS, Wu YL, Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957 (2009
4. Shaw AT, Kim DW, Nakagawa K., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385-2394 (2013
5. Kelly K, Altorki NK, Eberhardt WE., et al A randomized, double-blind Phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/ FISH) non-small cell lung cancer (NSCLC): RADIANT results. J. Clin. Oncol. 32(Suppl 5), Abstract 7501 (2014
6. Bradley JD, Paulus R, Komaki R., et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-Two factorial Phase 3 study. Lancet Oncol. 16(2), 187-199 (2015
7. Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol. 13(7), e301-e310 (2012
8. Gail MH A placebo-controlled randomized double-blind study of adjuvant intrapleural BCG in patients with resected T1N0, T1N1, or T2N0 squamous cell carcinoma, adenocarcinoma, or large cell carcinoma of the lung. LCSG Protocol 771. Chest 106, S287-S292 (1994
9. Holmes EC. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large cell undifferentiated carcinoma. Chest 106(6), S293-S296 (1994
10. Jansen RL, Slingerland R, Goey SH, Franks CR, Bolhuis RL, Stoter G. Interleukin-2 and interferon-Alpha in the treatment of patients with advanced non-small cell lung cancer. J. Immunother. 12(1), 70-73 (1992
11. Hirsh V, Paz-Ares L, Boyer M., et al. Randomized Phase III trial of paclitaxel/ carboplatin with or without PF-3512676 (toll-like receptor 9 agonist) as first-line treatment for advanced non-small cell lung cancer. J. Clin. Oncol. 29(19), 2667-2674 (2011
12. Manegold C, Van Zandwijk N, Szczesna A., et al A Phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small cell lung cancer. Ann. Oncol. 23(1), 72-77 (2012
13. Ramalingam S, Crawford J, Chang A., et al. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Ann. Oncol. 24, 2875-2890 (2013
14. Vansteenkiste JF, Cho BC, Vanakesa T., et al. MAGRIT, a double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC). Ann. Oncol. 25(Suppl 4), Abstract 1173O (2014
15. Butts C, Socinski MA, Mitchell PL., et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-smallcell lung cancer (START): a randomised, double-blind, Phase 3 trial. Lancet Oncol. 15(1), 59-68 (2014
16. Giaccone G, Bazhenova L, Nemunaitis J., et al A Phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small cell lung cancer (NSCLC). Eur. J. Cancer. 47(Suppl 2), Abstract LBA 7081 (2013
17. Quoix E, Losonczy G, Forget F., et al. TIME, a Phase 2B/3 study evaluating TG4010 in combination with first-line therapy in advanced non-small lung cancer (NSCLC). Phase 2B results. Ann. Oncol. 25(Suppl 4), Abstract 1055PD (2014
18. Takahashi K, Shichijo S, Noguchi M, Hirohata M, Itoh K. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res. 55(16), 3478-3482 (1995
19. Sienel W, Varwerk C, Linder A., et al. Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur. J. Cardiothorac. Surg. 25(1), 131-134 (2004
20. The International Adjuvant Lung Cancer Trial Collaborative Group, Arriagada R, Bergman B., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N. Engl. J. Med. 350, 351-360 (2004
21. Vansteenkiste J, Zielinski M, Linder A., et al. Adjuvant MAGE-A3 immunotherapy in resected non-small cell lung cancer: Phase II randomized study results. J. Clin. Oncol. 31, 2396-2403 (2013
22. Butts C, Murray N, Maksymiuk A., et al. Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small cell lung cancer. J. Clin. Oncol. 23, 6674-6681 (2005
23. Tecemotide news release. www.emdserono.com
24. Quoix E, Ramlau R, Westeel V., et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small cell lung cancer: a controlled Phase 2B trial. Lancet Oncol. 12, 1125-1133 (2011
25. Nemunaitis J, Dillman RO, Schwarzenberger PO., et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small cell lung cancer. J. Clin. Oncol. 24, 4721-4730 (2006
26. Gonzalez G, Crombet T, Catala M., et al A novel cancer vaccine composed of humanrecombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann. Oncol. 9, 431-435 (1998
27. Neninger Vinageras E, De La Torre A, Osorio Rodriguez M., et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small cell lung cancer. J. Clin. Oncol. 26, 1452-1458 (2008
28. Alfonso S, Valdes-Zayas A, Santiesteban ER., et al A randomized, multicenter, placebocontrolled clinical trial of racotumomabalum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin. Cancer Res. 20(14), 3660-3671 (2014
29. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-Tumor immunity. Curr. Opin. Immunol. 24, 207-212 (2012
30. Hodi FS, ODay SJ, McDermott DF., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010
31. Lynch TJ, Bondarenko I, Luft A., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small cell lung cancer: results from a randomized, double-blind, multicenter Phase II study. J. Clin. Oncol. 30, 2046-2055 (2012
32. Wolchok JD, Hoos A, ODay S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immunerelated response criteria. Clin. Cancer Res. 15, 7412-7420 (2009
33. Zatloukal P, Heo DS, Park K., et al. Randomised Phase II clinical trial comparing tremelimumab (CP-675206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 27(Suppl), Abstract 8071 (2015
34. Gettinger S, Horn L, Gandhi L., et al. Long-Term survival, clinical activity, and safety of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys. 90(Suppl), S34 (2014
35. Rizvi NA, Shepherd FA, Antonia SJ., et al. First-line monotherapy with Nivolumab (anti-DP-1; BMS-936558; ONO-4538) in advanced non-small cell lung cancer (NSCLC): safety, efficacy, and correlation of outcomes with PD-L1 status. Int. J. Radiat. Oncol. Biol. Phys. 90(Suppl), S31 (2014
36. Garon EB, Gandhi L, Rizvi NA., et al. Antitumor activity of pembrolizumab (pembro; MK-3475) and correlation with programmed dath ligand (PD-L1) expression in a pooled analysis of patients (pts) with advanced non-small cell lung cancer (NSCLC). Ann. Oncol. 25(Suppl 4), v1-v41 (2014
37. Soria JC, Gettinger S, Gordon M., et al. Biomarkers associated with clinical activity of PD-L1 blockade in non-small cell lung cancer (NSCLC) in a Phase I study of MPDL3280A. Ann. Oncol. 25(Suppl 4), iv426-iv470 (2014
38. Brahmer JR, Rizvi NA, Lutzky J., et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. J. Clin. Oncol. 32(Suppl 5), S511 (2014
39. Topalian SL, Hodi FS, Brahmer JR., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012
40. Rizvi NA, Mazieres J, Planchard D., et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a Phase 2, single-Arm trial. Lancet Oncol. 16(3), 257-265 (2015
41. Brahmer JR, Tykodi SS, Chow LQ., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012
42. Eisenhauer EA, Therasse P, Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009
43. Neuman HB, Patel A, Hanlon C, Wolchok JD, Houghton AN, Coit DG. Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Ann. Surg. Oncol. 14(10), 2847-2853 (2007
44. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 47, 207-214 (1981
45. Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Reserve. Clin. Cancer Res. 19, 3936-3943 (2015
46. Corsello SM, Barnabei A, Marchetti P, De VL, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab. 98, 1361-1375 (2013
47. Izzedine H, Gueutin V, Gharbi C., et al. Kidney injuries related to ipilimumab. Invest. New Drugs 32, 769-773 (2014
48. Ulloa-Montoya F, Louahed J, Dizier B., et al. Predictive gene signature in MAGEA3 antigen-specific cancer immunotherapy. J. Clin. Oncol. 31, 2388-2395 (2013
49. Highlights of OPDIVO prescribing information. www.accessdata.fda.gov
50. Garon EB, Ciuleanu TE, Arrieta O., et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, doubleblind, randomised Phase 3 trial. Lancet 384, 665-673 (2014
51. Reck M, Kaiser R, Mellemgaard A., et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUMELung 1): a Phase 3, double-blind, randomized controlled trial. Lancet Oncol. 15, 143-155 (2014
52. Soria JC, Cruz C, Bahleda R., et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). Eur. J. Cancer. 49(Suppl), Abstract 3408 (2013
53. Hellmann M D, Creelan B C, Woo K., et al. Smoking history and response to nivolumab in patients wiht advanced NSCLC. Ann. Oncol. 25(Suppl 4), Abstract 1229PD (2014
54. Gettinger S, Rizvi N, Chow LQ., et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinumbased doublet chemotherapy or erlotinib in advanced non-small cell lung cancer (NSCLC). Ann. Oncol. 25(Suppl 4), Abstract 1054PD (2014
55. Wolchok JD, Kluger H, Callahan MK., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013
56. Antonia SJ, Gettinger S, Goldman J., et al. Safety and efficacy of first-line nivolumab (anti-PD-1; BMS-936558; ONO-4538) and ipilimumab in non-small cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys. 90(Suppl), S32 (2014